The presence of pathogenic mutations in genes responsible for homologous recombination (HR) DNA repair opens up the possibility of therapy with PARP inhibitors (PARPi) in up to 25% of patients with metastatic castration-refractory PCA (CRPC) [9,10]. Here, PARP1 is linked to posterior cortical atrophy.